# Assess the Oral Bioavailability of New ABT-263 Formulations

> **NCT00743028** · PHASE1 · COMPLETED · sponsor: **Abbott** · enrollment: 36 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Lymphomas
- Leukemias

## Interventions

- **DRUG:** ABT-263
- **DRUG:** ABT-263
- **DRUG:** ABT-263

## Key facts

- **NCT ID:** NCT00743028
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2010-08
- **Final completion:** —
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2010-10-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00743028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00743028, "Assess the Oral Bioavailability of New ABT-263 Formulations". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00743028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*